NSCLC
-
药时代BD需求 | 寻找实体瘤项目，优先考虑消化系统肿瘤和EGFR突变的NSCLC
肺癌作为全球癌症致死率最高的恶性肿瘤，其临床需求持续升级。非小细胞肺癌（NSCLC）占据85%的发病量，其中EGFR基因突变以35%的全球突变率成为核心治疗靶点，亚洲人群突变率更高…
-
热烈祝贺第二款国产KRAS抑制剂获批上市！来自正大天晴和益方生物
药时代热烈祝贺！
-
One good drug can change fate! Summit’s stock price soars by 119%, with its market value increasing more than a hundredfold
For upcoming reports, please follow DrugTimes
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
-
罗氏TIGIT肺癌临床试验失利，决定提前终止II/III期研究
TIGIT，一个热门靶点，众多家药企布局，研发之路起起伏伏，挫折接二连三
-
Gilead | A Ray of Hope for the Highly Anticipated TROP2 ADC Trodelvy
DrugTimes team will follow up on this hot field and report timely. Please stay tuned. Many thanks!~
-
Is it too early for Akeso and Summit to celebrate? Merck executive comments on the explosive news that Keytruda has been successfully challenged
Just our two cents. All comments, including criticisms, are warmly welcome. Thank you all very much!
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
-
艾德生物与德国默克达成中国市场的伴随诊断战略合作
原文始发于微信公众号（药时代）：艾德生物与德国默克达成中国市场的伴随诊断战略合作 （来源：艾德生物） 2020年12月23日，中国厦门：继日本市场伴随诊断合作之后，艾德生物宣布已与…
-
真实世界中的度伐利尤单抗：III期NSCLC根治性放化疗后的巩固效果
原文始发于微信公众号（药时代）：真实世界中的度伐利尤单抗：III期NSCLC根治性放化疗后的巩固效果 本文转自：癌度，药时代授权转载，衷心感谢！ III期非小细胞肺癌（NSCLC）…
